Text this: Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments

  ______   _    _      _____    ______   _    _   
 /_____// | || | ||   / ___//  /_   _// | || | || 
 `____ `  | || | ||   \___ \\   -| ||-  | || | || 
 /___//   | \\_/ ||   /    //   _| ||_  | \\_/ || 
 `__ `     \____//   /____//   /_____//  \____//  
 /_//       `---`   `-----`    `-----`    `---`   
 `-`